Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance.
- NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_assertion description "[Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance.
- NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_assertion evidence source_evidence_literature NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance.
- NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_assertion SIO_000772 25468140 NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance.
- NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_assertion wasDerivedFrom befree-2016 NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance.
- NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_assertion wasGeneratedBy ECO_0000203 NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance.
- befree-2016 importedOn "2016-02-19" NP1244217.RA-Zh-h66X62VIdmIHQ19yo9H7a8Lw7sYDcy83WvAToT4130_provenance.